These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36481392)

  • 1. Cardiovascular Toxicity of Proteasome Inhibitors in Multiple Myeloma Therapy.
    Zheng Y; Huang S; Xie B; Zhang N; Liu Z; Tse G; Liu T
    Curr Probl Cardiol; 2023 Mar; 48(3):101536. PubMed ID: 36481392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management.
    Wu P; Oren O; Gertz MA; Yang EH
    Curr Oncol Rep; 2020 Jun; 22(7):66. PubMed ID: 32514632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management.
    Patel VG; Cornell RF
    Curr Oncol Rep; 2019 Mar; 21(4):29. PubMed ID: 30834998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma.
    Cole DC; Frishman WH
    Cardiol Rev; 2018; 26(3):122-129. PubMed ID: 29077585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.
    Ikoma T; Saotome M; Sano M; Suwa K; Naruse Y; Ohtani H; Urushida T; Nagata Y; Ono T; Maekawa Y
    Intern Med; 2019 Jun; 58(11):1577-1581. PubMed ID: 30713316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.
    Iannaccone A; Bruno G; Ravera A; Gay F; Salvini M; Bringhen S; Sabia L; Avenatti E; Veglio F; Milan A
    High Blood Press Cardiovasc Prev; 2018 Jun; 25(2):209-218. PubMed ID: 29582365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.
    Grandin EW; Ky B; Cornell RF; Carver J; Lenihan DJ
    J Card Fail; 2015 Feb; 21(2):138-44. PubMed ID: 25433360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence.
    Gavazzoni M; Vizzardi E; Gorga E; Bonadei I; Rossi L; Belotti A; Rossi G; Ribolla R; Metra M; Raddino R
    Eur J Pharmacol; 2018 Jun; 828():80-88. PubMed ID: 29550338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carfilzomib: A Tale of a Heartbreaking Moment: Case Report and Concise Review of the Literature.
    Serra W; Fantin A; Longo C; Rabia G; De Rosa F; Plenteda C; Re F; Crisafulli E; Chetta A
    Cardiovasc Hematol Disord Drug Targets; 2019; 19(3):253-258. PubMed ID: 30516116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta-analysis of randomized clinical trials.
    Das A; Dasgupta S; Gong Y; Shah UA; Fradley MG; Cheng RK; Roy B; Guha A
    Hematol Oncol; 2022 Apr; 40(2):233-242. PubMed ID: 34940983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Carfilzomib-Associated Cardiac Adverse Events.
    Mikhael J
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):241-5. PubMed ID: 26907720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.
    Danhof S; Schreder M; Rasche L; Strifler S; Einsele H; Knop S
    Eur J Haematol; 2016 Jul; 97(1):25-32. PubMed ID: 26331915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis.
    Shah C; Bishnoi R; Jain A; Bejjanki H; Xiong S; Wang Y; Zou F; Moreb JS
    Leuk Lymphoma; 2018 Nov; 59(11):2557-2569. PubMed ID: 29465266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome Inhibitors as a Potential Cause of Heart Failure.
    Koulaouzidis G; Lyon AR
    Heart Fail Clin; 2017 Apr; 13(2):289-295. PubMed ID: 28279415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies.
    El-Cheikh J; Moukalled N; Malard F; Bazarbachi A; Mohty M
    Blood Cancer J; 2023 May; 13(1):83. PubMed ID: 37208317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib.
    Shen X; Wu C; Lei M; Yan Q; Zhang H; Zhang L; Wang X; Yang Y; Li J; Zhu Y; Chen L
    Cell Death Dis; 2021 Apr; 12(5):429. PubMed ID: 33931582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.
    Cornell RF; Ky B; Weiss BM; Dahm CN; Gupta DK; Du L; Carver JR; Cohen AD; Engelhardt BG; Garfall AL; Goodman SA; Harrell SL; Kassim AA; Jadhav T; Jagasia M; Moslehi J; O'Quinn R; Savona MR; Slosky D; Smith A; Stadtmauer EA; Vogl DT; Waxman A; Lenihan D
    J Clin Oncol; 2019 Aug; 37(22):1946-1955. PubMed ID: 31188726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxicity with carfilzomib at doses greater than 27 mg/m
    Kim GY; Ahuja T; Papadopoulos J; Cirrone F
    J Oncol Pharm Pract; 2019 Jan; 25(1):229-233. PubMed ID: 28914153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.
    Fradley MG; Groarke JD; Laubach J; Alsina M; Lenihan DJ; Cornell RF; Maglio M; Shain KH; Richardson PG; Moslehi J
    Br J Haematol; 2018 Jan; 180(2):271-275. PubMed ID: 29048105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis.
    Bishnoi R; Xie Z; Shah C; Bian J; Murthy HS; Wingard JR; Farhadfar N
    Cancer Med; 2021 Jan; 10(1):70-78. PubMed ID: 33169938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.